Scott Friedman, Professor and Chief, Division of Liver Diseases at Mount Sinai School of Medicine, shared a post on LinkedIn:
“I am delighted and proud to share our paper published today in Science Translational Medicine, led by a tremendously talented MD / PhD student, Chittampalli Yashaswini (‘Yasha’). Along with our collaborators at U. Penn, we demonstrate reduced fibrosis in a MASH model in response to CAR T cells generated in vivo that deplete fibrogenic hepatic stellate cells (HSCs) expressing FAP (fibroblast activation protein).
Importantly, HSCs that support liver regeneration are unaffected, as depleting all HSCs would be unwise. An exciting, unexpected benefit was an improvement in liver health! These findings add to a growing list of potential indications for cell depletion strategies to treat serious, non-malignant diseases and reinforce the nuanced role of HSCs in regulating liver homeostasis and repair.”
Haig Aghajanian, Former Head of Research at Capstan Therapeutics, shared this post, adding:
“Exciting results from our collaboration with Scott Friedman and colleagues!
Another great example of how specific depletion of pathogenic cells via in vivo CAR T can lead to striking health benefits. In this case, liver fibrosis/MASH – an area of significant unmet medical need. Great work by everyone involved.”
Title: Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction–associated steatohepatitis
Authors: Chittampalli Yashaswini, Bruno Cogliati, Tianyue Qin, Tran To, Thomas Williamson, Tyler Papp, Kenneth Li, Raisa Rasul, Li Chen, Adi Lightstone, Haig Aghajanian, Hamideh Parhiz, Shuang Wang, Joel Rurik, Jonathan Epstein, Scott Friedman
Read the Full Article in Science Translational Medicine.
More posts featuring Haig Aghajanian on OncoDaily.